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Abstract
Objectie: To evaluate adrenal steroid hormone secretion in response to corticotropin-releasing factor (CRF) or to adrenocor-
ticotropin hormone in women with hypothalamic amenorrhea. Design: Controlled clinical study. Setting: Department of
Reproductive Medicine and Child Development, Section of Gynecology and Obstetrics, University of Pisa, Italy. Patient(s):
Fifteen women with hypothalamic amenorrhea were enrolled in the study. Eight normal cycling women were used as control
group. Interention(s): Blood samples were collected before and after an injection of ovine CRF (0.1 g/kg iv bolus) or after
synthetic ACTH (0.25 mg iv). Main outcome measure(s): Plasma levels of ACTH, 17-hydroxypregnenolone (17OHPe), proges-
terone (P), dehydroepiandrosterone (DHEA), 17-hydroxyprogesterone (17OHP), cortisol (F), 11-deoxycortisol (S) and androstene-
dione (A). Result(s): Basal plasma concentrations of ACTH, cortisol, 11-deoxycortisol, DHEA and 17OHPe were significantly
higher in patients than in controls, whereas plasma levels of progesterone and 17-OHP were significantly lower in patients than
in controls. In amenorrheic women the ratio of 17-OHPe/DHEA, of 17-OHPe/17-OHP and of 11-deoxycortisol/cortisol were
significantly higher than in controls, while a significant reduction in the ratio of 17-OHP/androstenedione, of 17-OHP/11-deoxy-
cortisol was obtained. In response to corticotropin-releasing factor test, plasma levels of ACTH, cortisol, 17-OHP, 11-deoxycor-
tisol, DHEA and androstenedione were significantly lower in patients than in controls. In response to adrenocorticotropin
hormone, plasma levels of 17-OHP, androstenedione and androstenedione/cortisol were significantly higher in patients than in
controls. Conclusions: Patients suffering for hypothalamic amenorrhea showed an increased activation of hypothalamus-pituitary-
adrenal (HPA) axis, as shown by the higher basal levels and by augmented adrenal hormone response to corticotropin-releasing
factor administration. These data suggest a possible derangement of adrenal androgen enzymatic pathway. © 2001 Elsevier
Science Ltd. All rights reserved.
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1. Introduction
Hypothalamic amenorrhea is a functional disorder
characterized by multiple abnormalities of the neuroen-
docrine control of hypothalamus-pituitary-ovarian axis.
Physical and psychological stressors may lead to amen-
orrhea throughout a neuroendocrine derangement [1].
Alterations of hypothalamic gonadotropin-releasing
hormone (GnRH) pulsatile secretion, as reflected by
changes in the characteristics of pulsatile luteinizing
hormone (LH) secretion, are typical findings in these
patients. A decrease in frequency and amplitude [2,3],
an increased frequency with a reduced amplitude [4] or
even an amplification of pulsatile LH release in associa-
tion with sleep [5,6] have been described. These alter-
ations of GnRH pulsatile secretion may be the result of
an impaired activity of central opioidergic or dopamin-
ergic neurons [7,8].
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Several studies described corticotropin-releasing fac-
tor (CRF) as a possible causal factor of reproductive
dysfunction in stressful conditions since in experimental
animals CRF produces a dose-related decrease in
GnRH release from the mediobasal hypothalamus in
vitro [9] and the decrease of LH plasma levels in vivo
[10–13]. Emotional, metabolic or physical stressors are
associated with an activation of hypothalamus-pitu-
itary-adrenal (HPA) axis in humans, which may lead to
hypercortisolemia as in hypothalamic amenorrhea
[3,14–18]. The increased cortisol (F) secretion depends
from a pulse frequency higher than in healthy women
during the daytime hours [18], but not during the
evening (16:00–24:00 h) or sleeping hours (24:00–08:00
h) [3]. Several possible mechanisms might be behind the
elevated cortisol production in hypothalamic amenor-
rhea, in particular an increased ACTH release and/or
an increased adrenal sensitivity to ACTH. Indeed, an-
other possibility could be a change in the adrenal
steroid pattern in favor of glucocorticoids. Dehydroepi-
androsterone (DHEA) and 17-hydroxyprogesterone
(17OHP) are the first steps on the two biosynthetic
pathways from the common substrate 17--hydroxy-5-
pregnenolone (17OHPe) to 3--hydroxy-5-ene andro-
gens and to cortisol (F), respectively. In fact, Zumoff et
al. [19] demonstrated a decrease in the adrenal 17,20-
lyase activity in women with anorexia nervosa with an
adrenal steroid metabolism mainly involved in gluco-
corticoid production by a shift towards 3-oxo-4-ene
C21-steroids as it has been reported in female en-
durance athletes [20].
On these basis, the present study aimed to evaluate
plasma cortisol and adrenal androgens concentrations
in women with hypothalamic amenorrhea before and
after CRF or ACTH stimulating test. Enzyme activity
will be evaluated as the precursor/product ratio of the
estimated contributions to the circulating steroids levels
as previously described [19–23].
2. Materials and methods
2.1. Subjects
Among women attending the Department of Ob-
stetrics and Gynecology at Pisa University, 15 (aged
18–31 years) suffering for hypothalamic amenorrhea
were enrolled for the study after informed consent. The
criteria for the inclusion of the patients were, (a) disap-
pearance of menses for at least 6 months before the
study; (b) no evidence of pregnancy; (c) absence of
metabolic or other endocrine diseases; (d) normal pro-
lactin (PRL) and thyroid hormone levels; (e) loss of
weight during the previous 18 months and a body mass
index (BMI) above 20. At the anamnestic evaluation all
patients had a variety of emotional-stressful events of
various nature preceding the onset of amenorrhea.
These events were mainly familiar and scholastic pres-
sures, working and psycho-social problems. Psychiatric
diseases were excluded using DSM-III criteria.
A group of eight normal cycling women (controls),
aged 24–32 years with normal BMI was taken as
controls and studied during the early follicular phase of
the menstrual cycle (days 4–5). None of these subjects
enrolled as control used hormonal preparations during
the 6 months preceding the study with normal BMI
(21.10.35).
2.2. Study design
After an overnight fast, all subjects were inserted an
indwelling catheter in an antecubital vein at 08:00 h,
kept open by slow infusion of a saline solution of NaCl
0.9% to avoid the effects of venopuncture as a stressor.
One hour later a baseline blood sample was collected
for the determination of plasma levels of LH, follicle-
stimulating hormone (FSH), PRL, 17-estradiol (E2),
ACTH, 17OHPe, progesterone (P), DHEA, dehy-
droepiandrosterone-sulfate (DHEAS), 17OHP, 11-de-
oxycortisol (S), F and androstenedione (A).
Immediately after this, all subjects received an intra-
venous bolus dose of ovine CRF (0.1 g/kg, Inalco,
Italy). Blood samples were taken 15, 30, 60, 90 and 120
min after the injection for ACTH, 17OHPe, P, DHEA,
17OHP, S, F and A determination.
After patients were administered 1 mg oral dexam-
ethasone at 23:00 h, the following day an ACTH stimu-
lation test was performed. Blood samples were done
immediately before the intravenous bolus of 0.25 mg
synthetic ACTH (0.25 mg, iv, Synacthen, Ciba-Geigy,
Switzerland) and 60 and 120 min after the corticotropin
administration. Control subjects underwent the stimula-
tions test during the early follicular phase of the subse-
quent menstrual cycle (days 3–4).
All blood samples were collected, centrifuged and
immediately frozen at −70 °C until assayed. For
ACTH determination ethylenediaminetetraacetic acid
(EDTA) containing glass tubes were used, placed on
ice, centrifuged at −4 °C and immediately frozen at
−70 °C until assayed.
The protocol has been approved by the Human
Investigation Committee of the University of Pisa.
2.3. Hormone assays and statistical analysis
All samples from each individual were analyzed in
duplicate in the same assay.
LH and FSH plasma levels were determined using a
specific time-resolved fluoroimmunoassay method
(Delfia, Wallac-Pharmacia & Upjhon, Milan, Italy)
whose intra-assay and the inter-assay coefficients of
variation (CVs) ranged from 3.7 to 4.5% and from 2.4
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to 3.8%, respectively, for LH and from 3 to 4% and
from 3.7 to 4.3%, respectively, for FSH. The sensitivity
of the fluoroimmunoassay method was 0.005 U/l.
Estradiol plasma levels were determined using a stan-
dard RIA (DPC-Medical Systems, Genova, Italy)
whose intra-assay and inter-assay CVs were 7.0 and
8.1%, respectively, with a sensitivity of 8 pg/ml. Pro-
lactin determination was performed using an immuno-
radiometric assay (Biodata-Biochem Immunosystems
Company, Milan, Italy) with a magnetic solid phase.
The intra-assay and the inter-assay CVs ranged from
3.2 to 5% and from 5.4 to 8%, respectively. The sensi-
tivity was 0.3 g/ml. Plasma P concentrations were deter-
mined using a standard RIA (Radim, Pomezia, Italy)
and 17OHP (Pantex, USA) were measured by RIA.
The intra- and inter-assay CVs were 4.8 and 9.2% for P
and 4.2 and 5.2% for 17OHP, respectively. The sensitiv-
ities were 0.1 and 0.2 nmol/l for P and 17OHP determi-
nation, respectively. The S and 17OHPe plasma
determination were performed using a RIA technique
(DRG Instruments, Marburg, Germany) after ether
extraction and celite columns purification. The intra-
and inter-assay CVs were 6.3 and 10.5% for S and 8.1
and 11.5% for 17OHPe, whereas the sensitivities were
0.3 and 0.07 nmol/l, for S and 17OHPe, respectively.
Plasma DHEAS and A were determined using a stan-
dard RIA technique (Radim) whose intra-assay and
inter-assay CVs were 6 and 8%, respectively, for
DHEAS and 5.1 and 8.9% for A. Plasma levels of
ACTH, F and DHEA were assayed using a RIA tech-
nique (ICN, Pharmaceutical, Orangeburg, NY, USA
for ACTH; Radim for F; DSL, Webster, TX, USA for
DHEA). The intra and inter-assay CVs were 6.3 and
10.8, 3.7 and 5.8, 5.4 and 8.9% for ACTH, F and
DHEA, respectively. The assay sensitivities were 2.0
pmol/l, 2.7 and 0.06 nmol/l for ACTH, F and DHEA,
respectively.
To evaluate adrenal response after CRF and ACTH
injections all data were normalized and analyzed as 
increase over basal values (). The maximum increase
(max) above baseline values of ACTH, 17OHPe, P,
DHEA, 17OHP, S, F and A in response to CRF and
the max over dexamethasone-suppressed baseline val-
ues of A, DHEAS, 17OHP and F in response to ACTH
were calculated to evaluate the adrenal androgen pro-
duction and cortisol secretion.
The activities of 3-hydroxysteroid dehydrogenase
and of 17,20-lyase and the other adrenal enzymatic
activities were calculated as the precursor/product ratio
of the estimated contributions to the circulating steroid
levels as previously described [19–22]. The adrenal
contribution for each steroid was taken as the net
difference in hormone concentration between either the
morning value (basal) and after a bolus of 0.1 g/kg
CRF (max) and between that after a bolus of 0.25 mg
ACTH (max) and the concentration after overnight
dexamethazone suppression.
Data were compared using Student’s t-test for paired
and unpaired data where appropriate after analysis of
variance to establish omogeinity of data using F-test.
3. Results
Hormonal characteristics of all groups of subjects are
summarized in Table 1 (meanS.E.). Basal plasma
concentrations of ACTH, 17OHPe, DHEA, S and F
were significantly (P0.01) higher in women with hy-
pothalamic amenorrhea than in control subjects (Table
1). Conversely, basal plasma levels of P and 17OHP
were significantly (P0.01) lower in amenorrheic
women than in healthy women (Table 1). No significant
difference between patients and normal women was
detected for A and DHEAS plasma levels (Table 1).
Women with hypothalamic amenorrhea showed a
ratio of 17OHPe/DHEA (marker of 17,20-lyase of 5
pathway), of 17OHPe/17OHP (marker of 3-hydroxys-
teroid-oxidoreductase-5–4-isomerase) and of S/F
(marker of 11-hydroxylase) significantly (P0.01)
higher than control subjects (Table 2). Moreover, ratio
of 17OHP/A and A/F (markers of 17,20-lyase of 4
pathway), of 17OHP/S and 17OHP/F (markers of 21-
hydroxylase) were significantly (P0.01) lower in
amenorrheic patients than in healthy women (Table 2).
No significant difference in the P/17OHP (marker of
17-hydroxylase of 4 pathway), DHEA/A (marker of
3-hydroxysteroid-oxidoreductase-5–4-isomerase) and
DHEAS/DHEA (sulfatase) ratios were observed be-
tween amenorrheic and normal women (Table 2).
After CRF administration, the adrenal response was
significantly lower (P0.01) in amenorrheic patients
than in control subjects. In fact amenorrheic women
showed a max response of ACTH, 17OHP, A, S,
Table 1
Baseline hormonal values of women participating in the study
Hypothalamic amenorrhea Controls
Number of subjects 815
BMI 21.90.28 21.10.35
LH (IU/l) 7.51.31.30.25*
FSH (IU/l) 3.10.89* 7.4 1.05
113.824.2E2 (pmol/l) 39.3312.35*
12.22.4PRL (g/l) 14.02.1
ACTH (nmol/l) 5.200.32* 2.480.52
17OHPe (nmol/l) 13.031.56* 3.480.51
1.350.81*P (nmol/l) 2.240.92
DHEA (nmol/l) 18.610.91* 11.670.82
DHEAS (mol/l) 3.680.272.750.43
1.120.22*17OHP (nmol/l) 2.290.31
6.360.74*S (nmol/l) 3.50.76
F (nmol/l) 44437* 33826
6.380.67A (nmol/l) 8.030.45
All values are reported as meanS.E. *, P0.01 vs. control subjects.
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Table 2
Adrenal precursor/product ratio in women with hypothalamic amen-
orrhea and in control subjects during the early follicular phase
Hypothalamic Controls
amenorrhae
Number of subjects 815
17OHPe/DHEA (17,20-lyase 0.730.11* 0.310.06
of 5 pathway)
2.120.3017OHPe/17OHP 7.770.56*
(3-hydroxysteroid-oxido-
reductase-5–4-isomerase)
S/F (11-hydroxylase) 0.0090.0010.0150.002*
17OHP/A (17,20-lyase of 4 0.280.13* 0.920.18
pathway)
0.0140.002* 0.0250.003A/F (17,20-lyase of 4
pathway)
17OHP/S (21-hydroxylase) 0.790.120.310.11*
0.0070.00117OHP/F (21-hydroxylase) 0.0030.001*
1.560.28 1.220.39P/17OHP (17-hydroxylase of
4 pathway)
3.040.66 4.130.43DHEA/A
(3-hydroxysteroid-oxido-
reductase-5–4-isomerase)
0.31+0.08DHEAS/DHEA (sulfatase) 0.140.05
All values are reported as meanS.E. *, P0.01 vs. control subject.
higher (P0.01) than healthy women (Fig. 2). No
significant difference for F and DHEAS responses to
ACTH injection was detected between amenorrheic and
normal women (data not shown). After ACTH admin-
istration, the adrenal ratio of A/F (marker of 17,20-
lyase of 4 pathway) was (P0.01) higher in patients
than in control subjects (Fig. 3). A slight, but not
significant, decrease was observed for the max re-
sponse of 17OHP/A in amenorrheic women after
ACTH stimulation test (Fig. 4). No significant differ-
ence for 17OHP/F response to ACTH injection was
detected between amenorrheic and normal women
(Fig. 3).
Fig. 2. max Increase over basal values of plasma levels of 17OHP,
androstenedione (A), DHEAS and cortisol (F) after ACTH (0.25 mg)
bolus. Amenorrheic subjects showed higher 17OHP and A responses.
Values are expressed in nmol/l as meanS.E. *, P0.01 hypothala-
mic amenorrhea (black column) vs. control subjects (white column).
Fig. 1. max Increase over basal values of plasma levels of proges-
terone (P), 17OHP, androstenedione (A), 11-deoxycortisol (S),
DHEA, cortisol (F), 17OHPe and ACTH after CRF (0.1 g/kg)
bolus. All hormones but P responses resulted reduced in amenorrheic
patients. Values are expressed in nmol/l as meanS.E. *, P0.01
hypothalamic amenorrhea (black column) vs. control subjects (white
column).
Fig. 3. Net change () of adrenal precursor/product ratio after
ACTH (0.25 mg) bolus in women with hypothalamic amenorhea
(black column) and in control subjects (white column). Only the A/F
ratio resulted higher in amenorrheic subjects. Values are expressed as
meanS.E. *, P0.01 hypothalamic amenorrhea (black column) vs.
control subjects (white column).
DHEA, F, 17OHPe significantly lower (P0.01) than
healthy subjects. No significant difference for P re-
sponse to CRF injection was detected between amenor-
rheic and normal women (Fig. 1). CRF injection did
not induce any significant differential response of any
adrenal precursor/product ratio between patients and
control subjects (data not shown).
After ACTH administration, amenorrheic women
showed a max increase of A and 17OHP significantly
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4. Discussion
The present study showed that women with hypotha-
lamic amenorrhea have a higher adrenal activity than
healthy subjects and suggested that such higher activity
reflects an altered function of specific adrenal enzymatic
pathways.
Hypothalamic amenorrhea is often associated with
stress-induced changes induced by metabolic, physical,
psychological stressors [15,24]. Indeed, loss of weight
for dieting and/or exaggerated training has been
demonstrated to alter several hormonal parameters af-
fecting not only the reproductive axis [4,24] but also
other endocrine glands such as thyroid [25,26], the
GH-RH-GH and IGF-1 axis [26] and the HPA axis
[15,18]. This last one has been extensively reported to
be modified during acute and/or chronic stress
[10,11,13,15,18] as well as in psychiatric disorders [27],
both in plasma and in cerebrospinal fluid [27]. Previous
studies [19] proposed that such modification of adrenal
function might be related to some altered enzymatic
pathway. Indeed cortisol and androgens are biosynthet-
ically derived from a common precursor, 17OHPe: the
step to cortisol is mediated by 3-hydroxysteroid dehy-
drogenase while the initial step to DHEA is mediated
by 17,20-lyase. Since these two pathways are true alter-
native branches from the common precursor, the pre-
cursor/product ratio can be considered as an index of
the relative activities of the two enzymes. Our data
clearly showed that patients with hypothalamic amen-
orrhea have a decreased 17,20-lyase 5 and 4 enzy-
matic activity, confirming previous reports in anorexia
nervosa [19]. Indeed, these authors suggested also that
the decreased adrenal 17,20-lyase activity, typical in
prepubertal children, may constitute a specific parame-
ter to support the hypothesis that hypothalamic amen-
orrhea is a sort of functional regression to a
prepubertal state. The hypothesis, that a reduced activ-
ity of 17,20-lyase of adrenal 5 pathway may explain
the increased 17OHPe plasma levels in hypothalamic
amenorrhea, is strongly supported. Such excess in
17OHPe concentrations has a specific biological rele-
vance since is finalized towards cortisol secretion. This
hypothesis is strongly supported by the increased enzy-
matic activity of 21-hydroxylase we observed in amen-
orrheic subjects.
The present data suggest that in women with hypo-
thalamic amenorrhea the adrenal steroid metabolism is
shifted in favor of cortisol secretion, as demonstrated
by the higher cortisol levels. The adrenal androgen
concentrations in presence of hypoestrogenism and re-
duced plasma SHBG concentrations may explain the
signs of moderate hirsutism that are often observed in
amenorrheic patients.
The adrenal hypersecretion of cortisol is likely to be
mediated through an increased hypothalmic CRF drive
[18]. In fact, our data confirmed a blunted ACTH and
F response to CRF test in women with hypothalamic
amenorrhea [16,18] and showed that the max increase
over basal values of DHEA, 17OHP, S and A in
women with hypothalamic amenorrhea was lower than
in control subjects. Two hypotheses could be proposed
to explain such reduced response of adrenal steroids in
amenorrheic women, (1) a defect in enzymatic activity
at the adrenal gland level; (2) an increased functional
activation of the HPA axis via CRF overproduction. In
support to this last hypothesis, there is the observation
that hypothalamic amenorrhea shows a relatively high
response of plasma levels of ACTH to acute CRF
injection in relation to an increased endogenous CRF
tone that reduces anterior pituitary sensitivity to en-
dogenous CRF stimulation. Moreover, this leads to
adrenal ACTH receptors down-regulation and to a
blunted cortisol and androgen responses to CRF ad-
ministration [16].
Under ACTH test, no significant difference in the
max response of F and DHEAS was observed be-
tween amenorrheic and normal women, whereas the
max increase over basal values of A and 17OHP was
significantly higher in women with hypothalamic amen-
orrhea than in control subjects. Interestingly such data
support a 17,20-lyase activity of 4 pathway signifi-
cantly higher than healthy women. Thus, our data show
that the ACTH stimulation test in amenorrheic women
reveals an increased adrenal cortex activity. Thus sup-
porting that adrenal response to ACTH stimulation test
seems to induce more androgen production rather than
cortisol secretion. However, it cannot be excluded that
minimal modifications of clearance rate of steroids
might participate to determine the increase of androgen
plasma levels.
In conclusion, the present data showed that in hypo-
thalamic amenorrhea the basal activity of HPA axis
was increased and report a reduced sensitivity of the
anterior pituitary to CRF stimulation, in absence of
any altered sensitivity of the adrenal cortex. Moreover,
the reduced adrenal androgen secretion we observed in
basal conditions in women with hypothalamic amenor-
rhea suggests a redistribution of adrenal steroid
metabolism in favor of cortisol. Whether this physio-
pathological situation depends or not from a genetically
based predisposition remains to be determined in fol-
lowing studies.
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